CYP2C19*2 polymorphism is associated with increased survival in breast cancer patients using tamoxifen.

AIMS Variant alleles of the CYP2C19 gene were recently associated with survival in breast cancer patients on tamoxifen therapy. CYP2C19 is one of the enzymes involved in the metabolism of tamoxifen into active metabolites. We investigated the hypothesis that CYP2C19*2 and *3 variants, known for their lack of enzyme activity, are associated with an increased breast cancer mortality rate in patients using tamoxifen. MATERIALS & METHODS In the prospective population based Rotterdam study, the association between CYP2C19*2 carriers and breast cancer mortality was studied among 80 incident users of tamoxifen. Survival was analyzed with life tables and Cox regression analysis, with drug exposure as a time-dependent variable. Adjustments were made for calendar time, average tamoxifen dose, age, the indication for tamoxifen, CYP2D6 genotype and concomitant use of CYP2C19 inhibitors or inducers. RESULTS In patients on tamoxifen, CYP2C19*2 carriers were associated with a significantly longer breast cancer survival rate than patients with the wild-type (hazard ratio 0.26, 95%CI: 0.08-0.87). CONCLUSION This study suggests that CYP2C19 genotype may possibly be a predictive factor for survival in breast cancer patients using tamoxifen.

[1]  B. Bonanni,et al.  Efficacy of tamoxifen based on cytochrome P450 2D6, CYP2C19 and SULT1A1 genotype in the Italian Tamoxifen Prevention Trial , 2011, The Pharmacogenomics Journal.

[2]  Hein Putter,et al.  Effect of concomitant CYP2D6 inhibitor use and tamoxifen adherence on breast cancer recurrence in early-stage breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  W. Newman,et al.  The Impact of CYP2D6 Genotyping on Tamoxifen Treatment , 2010, Pharmaceuticals.

[4]  B. Stricker,et al.  Analysis of individual drug use as a time-varying determinant of exposure in prospective population-based cohort studies , 2010, European Journal of Epidemiology.

[5]  Yusuke Nakamura,et al.  Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  M. Goetz,et al.  Genetic polymorphisms of CYP2D6*10 and CYP2C19*2, *3 are not associated with prognosis, endometrial thickness, or bone mineral density in Japanese breast cancer patients treated with adjuvant tamoxifen , 2010, Cancer.

[7]  S. Sleijfer,et al.  CYP-2C19*2Predicts Favorable Outcome of Tamoxifen Treatment for Advanced Breast Cancer. , 2009 .

[8]  M. Beckmann,et al.  Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. , 2009, JAMA.

[9]  H. Sørensen,et al.  Genotype-guided tamoxifen therapy: time to pause for reflection? , 2009, The Lancet. Oncology.

[10]  D. Hochstrasser,et al.  The AmpliChip CYP450 test: cytochrome P450 2D6 genotype assessment and phenotype prediction , 2009, The Pharmacogenomics Journal.

[11]  C. V. D. van de Velde,et al.  Clinical Implications of CYP2D6 Genotyping in Tamoxifen Treatment for Breast Cancer , 2009, Clinical Cancer Research.

[12]  Monique M. B. Breteler,et al.  The Rotterdam Study: 2016 objectives and design update , 2015, European Journal of Epidemiology.

[13]  C. Alonso,et al.  Impact of CYP2D6 polymorphisms in tamoxifen adjuvant breast cancer treatment , 2009, Breast Cancer Research and Treatment.

[14]  H. Brauch,et al.  CYP2C19*17 is associated with decreased breast cancer risk , 2009, Breast Cancer Research and Treatment.

[15]  A. Hofman,et al.  The CYP2D6*4 polymorphism affects breast cancer survival in tamoxifen users , 2009, Breast Cancer Research and Treatment.

[16]  D. Evans,et al.  Impaired Tamoxifen Metabolism Reduces Survival in Familial Breast Cancer Patients , 2008, Clinical Cancer Research.

[17]  S. Shi,et al.  Proton pump inhibitors: an update of their clinical use and pharmacokinetics , 2008, European Journal of Clinical Pharmacology.

[18]  Sabine Siesling,et al.  Recent trends of cancer in Europe: a combined approach of incidence, survival and mortality for 17 cancer sites since the 1990s. , 2008, European journal of cancer.

[19]  Wolfgang Simon,et al.  Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  S. Wingren,et al.  Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer , 2007, Breast Cancer Research.

[21]  Zeruesenay Desta,et al.  Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: Implication for optimization of breast cancer treatment , 2006, Clinical pharmacology and therapeutics.

[22]  David A. Flockhart,et al.  The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen , 2006, Breast Cancer Research and Treatment.

[23]  Fergus J Couch,et al.  Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  Y Wang,et al.  Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.

[25]  J. Ferlay,et al.  Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.

[26]  David A. Flockhart,et al.  CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. , 2005, Journal of the National Cancer Institute.

[27]  J. Scheys,et al.  Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients , 2005, Breast Cancer Research and Treatment.

[28]  T. Skaar,et al.  Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen , 2005, Cancer Chemotherapy and Pharmacology.

[29]  L. Skoog,et al.  Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients , 2005, Breast Cancer Research.

[30]  David A. Flockhart,et al.  Comprehensive Evaluation of Tamoxifen Sequential Biotransformation by the Human Cytochrome P450 System in Vitro: Prominent Roles for CYP3A and CYP2D6 , 2004, Journal of Pharmacology and Experimental Therapeutics.

[31]  T. Skaar,et al.  Pharmacological Characterization of 4-hydroxy-N-desmethyl Tamoxifen, a Novel Active Metabolite of Tamoxifen , 2004, Breast Cancer Research and Treatment.

[32]  A. Hofman,et al.  Determinants of disease and disability in the elderly: The Rotterdam elderly study , 1991, European Journal of Epidemiology.

[33]  Zeruesenay Desta,et al.  Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. , 2003, Journal of the National Cancer Institute.

[34]  K. Turteltaub,et al.  Identification of human CYP forms involved in the activation of tamoxifen and irreversible binding to DNA. , 2002, Carcinogenesis.

[35]  E. Gillam,et al.  Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4'-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[36]  M. Eichelbaum,et al.  The influence of CYP2B6, CYP2C9 and CYP2D6 genotypes on the formation of the potent antioestrogen Z-4-hydroxy-tamoxifen in human liver. , 2002, British journal of clinical pharmacology.

[37]  J. Jonkman,et al.  An optimized methodology for combined phenotyping and genotyping on CYP2D6 and CYP2C19 , 2001, European Journal of Clinical Pharmacology.

[38]  S. Dehal,et al.  CYP2D6 catalyzes tamoxifen 4-hydroxylation in human liver. , 1997, Cancer research.

[39]  G. Tucker,et al.  Variable contribution of cytochromes P450 2D6, 2C9 and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes. , 1997, Biochemical pharmacology.

[40]  M. Rowlands,et al.  Analysis of phase I and phase II metabolites of tamoxifen in breast cancer patients. , 1993, Drug metabolism and disposition: the biological fate of chemicals.

[41]  P. Ueland,et al.  Identification of 4-hydroxy-N-desmethyltamoxifen as a metabolite of tamoxifen in human bile. , 1988, Cancer research.

[42]  M. Kimmel,et al.  Estrogen Receptor Protein of Breast Cancer in Patients With Positive Nodes: High Recurrence Rates in the Postmenopausal Estrogen Receptor—Negative Group , 1987 .

[43]  V. Jordan,et al.  A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity. , 1977, The Journal of endocrinology.